Introduction {#s1}
============

Dilated cardiomyopathy (DCM: OMIM 115200), is characterized by cardiac left ventricular dilation and systolic dysfunction, affects at least 1 in 2500 individuals [@pone.0101451-Codd1], and a major cause for morbidity and mortality [@pone.0101451-Knoll1], including heart failure (HF) and sudden cardiac death (SCD) [@pone.0101451-Ackerman1]--[@pone.0101451-Wiles1]. Familial DCM (FDCM) is a genetically heterogeneous disease [@pone.0101451-Hershberger1], whereas Idiopathic DCM (IDCM) is diagnosed when clinically detectable causes of DCM are excluded. Genetic screening of first-degree relatives had revealed, approximately 20 to 35% of idiopathic cases, were due to genetic defects [@pone.0101451-Hershberger1]--[@pone.0101451-Judge1]. More than 30 nuclear genes, encoding for sarcomere (contractile apparatus), cytoskeletal and calcium homeostasis proteins of diverse functions, have been reported to cause FDCM [@pone.0101451-Hershberger1]. To date, mutations in *LMNA, MYH7, MYBPC3, TNNT2, SCN5A*, and *MYH6* genes have been accounted for approximately 75% of FDCM [@pone.0101451-Hershberger2]. Most of the genes implicated in genetics of DCM/FDCM follow autosomal dominant mode of inheritance \[6\], though a few follow autosomal recessive, X-linked [@pone.0101451-Burkett1], [@pone.0101451-Hershberger3]--[@pone.0101451-Santorelli1] and mitochondrial [@pone.0101451-Santorelli1], [@pone.0101451-Li1]. Recent studies had suggested that the double and triple mutations identified in sarcomere protein genes were found to be associated with early onset of HCM [@pone.0101451-Ingles1], [@pone.0101451-Girolami1].

Indian populations are reported to be more prone to cardiac disorders, which might be due to their high effective population size (Ne) and lifestyle, resulting a unique genetic structure [@pone.0101451-Dhandapany1]--[@pone.0101451-Metspalu1]. Our previous study on cardiac Troponin I3 (*TNNI3*) [@pone.0101451-Rani1], [@pone.0101451-Ramachandran1] and Troponin T2 (*TNNT2*) [@pone.0101451-Rani2] in hypertrophic cardiomyopathy (HCM), and cardiac actin (*ACTC*) [@pone.0101451-Rangaraju1], myosin binding protein C (*MyBPC3*) [@pone.0101451-Dhandapany1], had revealed few variants, of which a 25 bp deletion was found to be associated with both HCM and DCM in India and south Asia [@pone.0101451-Dhandapany1]. Unfortunately, not many studies have been conducted on Indian patients to explore the genetic etiology of the disease, particularly with reference to the sarcomere protein genes. Our aim in the present study is to investigate the genetic variations in Troponin T (*cTnT*) gene, and its association with DCM in South Indian cohorts.

Results {#s2}
=======

Sequencing of all the exons and the exon-intron boundaries (5373 bp) of Troponin T2 (*cTnT*) gene in 147 DCM patients along with 207 healthy controls had revealed a total of 15 SNPs and a 5 bp INDEL ([Fig. 1A to 1M](#pone-0101451-g001){ref-type="fig"} and [Table 1](#pone-0101451-t001){ref-type="table"}).

![1A-1M: Electropherograms showing SNPs of cTnT gene, observed in the present study on South Indian dilated cardiomyopathy patients.\
Mutation sites were shown with arrows. **Fig. 1A** **. R144W** \[rs483352832\]: Electropherogram (arrow) showing a novel missense mutation (R144W) at the nucleotide position g.14351 of human cTnT gene. The upper lane showing sequences of homozygous wild type allele 'C' in a control individual. The middle and the lower lanes were showing the sequences of heterozygous (C/T  = Y) alleles in two individuals (a DCM patient and his relative, respectively). **Fig. 1B. G\>A \[IVS11-1G\]** \[rs483352835\]: Electropherogram (arrow) showing a variant at splice acceptor site of human *cTnT* gene at nucleotide position g.16283, the electropherogram of a upper lane showing sequence of heterozygous (A/G = R) variant in a DCM patient, the lower lane showing sequence of control individual having wild type allele 'G' (homozygous). **Fig. 1C. N164N** \[rs483352833\]: Electropherogram (arrow) showing a novel synonumous mutation (N164) at the nucleotide position g.15304 of human *cTnT* gene in 2 DCM patients. The upper lane shows the sequences of heterozygous (C/T  = Y) transition in a DCM patient. The middle lane was the sequences of a control individual showing the wild type allele 'C' (homozygous). The lower lane sequences showing heterozygous (C/T  = Y) transition was from a 2^nd^ DCM patient. **Fig. 1D**. \[rs3729842\]: Electropherogram showing (arrow) a single nucleotide polymorphism at the nucleotide position g.10636 (C/T = Y) in intron 5 of human *cTnT* gene. The upper and the middle lanes were sequences showing heterozygous (C/T = Y) transition in DCM patients, the lower lane showing homozygous wild type (C/C) allele in a control individual. **Fig. 1E**. \[rs3729845\]: Electropherogram showing (arrow) at the nucleotide position g.13011 of human *cTnT* gene. The upper lane showing sequences of the heterozygous (A/G  = R) transition, and the lower lane showing homozygous wild type (G/G) allele of a control. **Fig. 1F**. \[rs1104859\]: Electropherogram showing (arrow) at the nucleotide position **g.11643** (A/C = M) in Intron 11 of human *cTnT* gene. The upper lane sequences showing the heterozygous (A/C = M) transversion, the middle lane showing homozygous wild type (G/G), and the lower lane sequences showing mutant homozygous (C/C) allele. **Fig.1G** **. SNP-rs3729843**: Electropherogram showing (arrow) a SNP at the nucleotide position g.10822 (G/A = R) in intron 5 of human *cTnT* gene. The upper lane sequences showing mutant homozygous (A/A) allele. The middle lane sequences showing heterozygous (G/A = R) transition allele, and the lower lane showing sequences of homozygous wild type (G/G) allele in a control individual. **Fig. 1H**. \[rs45576939\]: Electropherogram showing (arrow) a novel mutation G\>A at nucleotide position g.10370 in intron 4 of human *cTnT* gene, the upper lane displaying homozygous mutant (A/A) allele, and the lower lane showing sequences of a wild type allele (G/G). **Fig. 1I**. \[rs45576635\]: Electropherogram showing (arrow) a SNP at the nucleotide position g.14492 (C/T = Y) in intron 15 of human *cTnT* gene, the upper and the middle lanes sequences displaying heterozygous (C/T = Y) transition, and the lower lane sequences showing homozygous wild type (C/C) allele. **Fig. 1J**. \[rs3729547\]: Electropherogram showing (arrow) a polymorphic variant at the nucleotide position g.13424 of human *cTnT* gene, the upper lane displaying sequences of the heterozygous (C/T  = Y) transition, the middle lane sequences showing homozygous wild type (C/C) allele, and the lower lane displaying sequences of the homozygous mutant (T/T) allele. **Fig. 1K**. \[rs483352834\]. Electropherogram (arrow) showing a novel mutation at the nucleotide position g.15179 C\>T in intron 11 of human *cTnT* gene, the upper lane displaying sequences of a DCM patient having heterozygous (C/T) transition, and the lower lane exhibiting sequences of a control individual having homozygous wild type allele (C/C). **Fig. 1L. K276K**. \[rs483352836\]: Electropherogram (arrow) exhibiting novel synonumous (K276) variant at the nucleotide position g.19429 of human *cTnT* gene in a DCM patient, the DCM patient displaying heterozygous (G/A  = R) transition. **Fig. 1M**. Sequence electropherogram showing (CTTCT) 5 bp Polymorphism. **Ma**. Presence of two copies of CTTCT (Insertion/Insertion -- homozygous insertion) in both the chromosomes, **Mb**. Absence of one copy of CTTCT (Deletion/Deletion -- homozygous deletion in both the chromosomes, **Mc**. Presence of 2 copies of CTTCT in one chromosome and presence of one copy of CTTCT in another chromosome (Insertion/deletion -- heterozygous allele). g.6626-30 (5 bp).](pone.0101451.g001){#pone-0101451-g001}

10.1371/journal.pone.0101451.t001

###### Total number of mutations observed in Troponin T (*cTnT*) gene.

![](pone.0101451.t001){#pone-0101451-t001-1}

  S:NO    Chromosome position   Genomic position   Major \>Minor allele   Location    SNP Reference   AA Change   Novel   PolyPhen_2     SIFT     Predictions   CON/207   DCM/147
  ------ --------------------- ------------------ ---------------------- ----------- --------------- ----------- ------- ------------ ---------- ------------- --------- ---------
  1          1201341276-80         g.6626-30             \[5 bp\]         Intron 3        5 bp           \_        \_         \_          \_          \_          HP        HP
  2           1201337436            g.10370                G\>A           Intron 4     rs45576939        \_        \_         \_          \_          \_           0         1
  3           1201337170            g.10636                C\>T           Intron 5      rs3729842        \_        \_         \_          \_          \_          HP        HP
  4           1201336984            g.10822                G\>A           Intron 6      rs3729843        \_        \_         \_          \_          \_          HP        HP
  5           1201335899            g.11907                A\>G           Intron 7      rs1573230        \_        \_         \_          \_          \_           1         0
  6           1201334795            g.13011                G\>A            Exon 8       rs3729845       S69S       \_         \_          \_          \_           0         2
  7           1201334382            g.13424                C\>T            Exon 9       rs3729547       I106I      \_         \_          \_          \_          HP        HP
  8           1201333455            g.14351                C\>T            Exon 10     rs483352832      R144W     Novel    Damaging    Damaging   Pathogenic       0         1
  9           1201332502            g.15304                C\>T            Exon 11     rs483352833      N164N     Novel       \_          \_          \_           0         2
  10          1201332603            g.15179                C\>T           Intron 11    rs483352834      Novel     Novel       \_          \_          \_           0         1
  11          1201331554            g.16252               \[AC\]          Intron 11     rs1104859        \_        \_         \_          \_          \_          HP        HP
  12          1201331523            g.16283                G\>A           Intron 11    rs483352835       SS        \_         \_          \_          \_           0         1
  13          1201328824            g.18982                C\>T           Intron 14     rs2275863        \_        \_         \_          \_          \_           P         P
  14          1201328705            g.19101                C\>T           Intron 15    rs45576635        \_        \_         \_          \_          \_           0         2
  15          1201328913            g.18893                C\>T           Intron 16    rs45509695        \_        \_         \_          \_          \_           0         4
  16          1201328377            g.19429                G\>A            Exon 16     rs483352836      K276K      \_         \_          \_          \_           0         2

\*SNP- single nucleotide polymorphism, AA-Amino Acid, CON- Controls, DCM- Dilated cardiomyopathy, SS- Splice Site, HP-Highly Polymorphic.

Arginine to Tryptophan substitution at residue 144 (R144W) of cTnT gene {#s2a}
-----------------------------------------------------------------------

Of the 15 SNPs, a unique c.430 C\>T transition (GenBank No. NM_000364) in exon 10 of *TNNT2* gene, identified in a 29 years old male DCM patient, is of great interest, as the mutation replaces the highly conserved basic amino acid arginine at residue 144 to polar-neutral tryptophan R144W \[rs483352832\] ([Fig. 1A](#pone-0101451-g001){ref-type="fig"}). The R144W mutation has resulted with loss of restriction sites; *Mbil* 19, *Acil* 19, *BsrBl* 19, *AccBSl* 19. Subsequent, screening of this (R144W) mutation with available family members had revealed its presence in three other individuals with DCM phenotype ([Fig. 2](#pone-0101451-g002){ref-type="fig"}). However, this mutation was absent in 207 healthy unrelated controls, and in 162 HCM patients [@pone.0101451-Rani2]. Multiple alignment of the amino acid with different species had revealed that the arginine at 144 in human *cTnT* is evolutionarily conserved across species; including mammals, birds, reptiles, and nematode ([Fig. 3](#pone-0101451-g003){ref-type="fig"}).

![The pedigree of a familial dilated cardiomyopathy patient (FDCM) having R144W mutation in the exon 10 of cardiac Troponin T2 (*cTnT*) gene.\
Squares indicate males; circles, females; open symbols, normal individuals; solid symbols, affected individuals, Slanted bars indicate deceased members of family. Plus signs indicate the presence of R144W mutation in *cTnT*; minus signs suggest the absence of mutation R144W in *cTnT*.](pone.0101451.g002){#pone-0101451-g002}

![The amino acid arginine at residue 144 in human Troponin T (*cTnT*) is highly conserved across many species, including mouse, rat, chicken, rabbit, sheep and bovine.](pone.0101451.g003){#pone-0101451-g003}

While interacting with the family members of the proband, a history of sudden cardiac deaths (SCD) in the family was noted. Two individuals in the family, who were diagnosed with DCM, had died due to severe congestive heart failure at the age of 45 and 25 years. However, a 66-year-old individual in the same family with DCM having mild symptoms have also been noticed. Thus indicating that the age of onset, and the severity of the disease are highly variable within the family ([Fig. 2](#pone-0101451-g002){ref-type="fig"} and, [Table 2](#pone-0101451-t002){ref-type="table"}).

10.1371/journal.pone.0101451.t002

###### Clinical details of the family members carrying R144W mutation.

![](pone.0101451.t002){#pone-0101451-t002-2}

  Generations (G)     Sex     Genotype (R144W) Positive   Age (in years)   Age of onset (in years)   NYHA III or IV   Mitral Regurgitation   Ventricular arrhythmia   LVIDd (mm)   LVEF (%)
  ----------------- -------- --------------------------- ---------------- ------------------------- ---------------- ---------------------- ------------------------ ------------ ----------
  G-III^rd^           Male               YES                    66                   60                   YES                 MOD                     YES                 67          30
  G-IV^th^            Male            NK (SCD)                  45                   44                   YES                 SEV                     YES                 NK          NK
  G-IV^th^           Female              YES                    39                   30                   YES                 MOD                     YES                 71          29
  G-IV^th^            Male            NK (SCD)                  25                   24                   YES                 SEV                     YES                 NK          NK
  G-V^th^             Male               YES                    29                   25                   YES                 SEV                     YES                 72          26
  G-V^th^             Male               YES                    19                   15                   YES                 MILD                     NO                 55          34

SCD- Sudden cardiac death; NYHA-New York Heart Association; LVIDd- left ventricular internal diastolic dimension; LVEF- left ventricular ejection fraction.

A novel splice acceptor site variant {#s2b}
------------------------------------

We have also identified a novel splice acceptor site variant (G→A) in intron 12 of *cTnT* gene \[rs483352835\], in a 63 years old male DCM patient ([Fig. 1B](#pone-0101451-g001){ref-type="fig"} and, [Table 1](#pone-0101451-t001){ref-type="table"}). This patient had both dilated LV/LA, with EF 25%, global hypokinesia, grade III systolic dysfunction, and IVS thinned out 7 mm. Unfortunately, we were unable to get the family samples for additional analyses.

Two novel synonymous mutations {#s2c}
------------------------------

We further identified two novel synonymous mutations, N164N (C→T; \[rs483352833\]) and K276K (G→A; \[rs483352836\]) in *cTnT* gene ([Fig. 1C and 1L](#pone-0101451-g001){ref-type="fig"}, [Table 1](#pone-0101451-t001){ref-type="table"}) exclusively in DCM. Of which, N164N ([Fig. 1C](#pone-0101451-g001){ref-type="fig"}) was observed in 2 DCM (2/147 = 1.4%) patients with EF of 35% (a 35 year old female) and 30% (39 year old male). The codon bias analysis had revealed a replacement of more frequently used (wild type) codon (AAC: 64%) with a less frequent one (AAT: 36%) ([Table 3](#pone-0101451-t003){ref-type="table"}). The female patient showed both dilated left ventricle and atrium, moderate mitral regurgitation and moderate LV systolic dysfunction, while the male patient showed LV dilation and moderate LV systolic dysfunction.

10.1371/journal.pone.0101451.t003

###### The codon usage in human cTnT (Genbank NO. NM_000364) gene.

![](pone.0101451.t003){#pone-0101451-t003-3}

  S:NO    Chr. position   Position      SNP. Ref       Location   Nt. Change   A.A Site    Type    Codon     Amino acid     Fraction   \%   Frequency   Codon Useage
  ------ --------------- ---------- ----------------- ---------- ------------ ---------- -------- ------- ---------------- ---------- ---- ----------- --------------
  1        1201334795     g.13011       rs3729845       Exon 8       G/A        79^th^     Wild     TCG      Serine (S)      0.125     13     3.46           1
                                                                                          Mutant    TCA      Serine (S)        0       0        0            0
  2        1201334382     g.13424       rs3729547       Exon 9       C/T       116^th^     Wild     ATC    Isoleucine (I)    0.667     67     27.68          8
                                                                                          Mutant    ATT    Isoleucine (I)     0.25     25    10.381          3
  3        1201332502     g.15304    **rs483352833**   Exon 11       C/T       164^th^     Wild     AAC    Asparagine (N)    0.692     69    31.142          9
                                                                                          Mutant    AAT    Asparagine (N)    0.308     31    13.841          4
  4        1201328377     g.19429    **rs483352836**   Exon 16       G/A       276^rd^     Wild     AAG      Lysine (K)      0.758     76    86.505          25
                                                                                          Mutant    AAA      Lysine (K)      0.242     24    27.682          10

Chr- Chromosome, SNP- Single Nucleotide Polymorphism, Ref- References, Nt. Nucleotide, A.A-Amino Acid.

The K276K synonymous mutation ([Fig. 1L](#pone-0101451-g001){ref-type="fig"}; rs483352836) was observed in 2 DCM patients (2/147 = 1.4%), which replaces very frequent codon (71%; AAG) with the less frequent codon (29%; AAA) ([Table 3](#pone-0101451-t003){ref-type="table"}). Though these two (N164N; K276K) mutations were synonymous, its exclusive presence in dilated cardiomyopathy patients, illustrates its possible role in disease pathogenesis, however, they need to be studied further.

Two intronic SNPs and their splicing patterns {#s2d}
---------------------------------------------

We found two intronic SNPs of *cTnT* gene (G→A; g.10370\_ \[rs45576939\] and C→T; g.15179- \[rs483352834\]), exclusively in DCM patients. *In silico* analyses had predicted abnormal splicing pattern ([Table 4](#pone-0101451-t004){ref-type="table"}). The G→A variant was found to create an additional binding site for [hnRNP. K1K2]{.ul} ([Fig. 1H](#pone-0101451-g001){ref-type="fig"} and, [Table 4](#pone-0101451-t004){ref-type="table"}), while the C→ T variant was also causes drastic changes by altering a total of 4 binding sites, 2 each in hnRNPs and SR proteins ([SRP20 ASF/SF2, SC35]{.ul} and [U2AF65]{.ul}) ([Fig. 1K](#pone-0101451-g001){ref-type="fig"} and, [Table 4](#pone-0101451-t004){ref-type="table"}), indicating its regulatory role, however, its clinical significance need to be studied further.

10.1371/journal.pone.0101451.t004

###### The hn-RNP\'s and SR-proteins binding site sequences in controls and DCM as predicted by "Splicing Rainbow" tool.

![](pone.0101451.t004){#pone-0101451-t004-4}

  S. No    Chromosome Position/rs number      Position      Location    Splicing Rainbow & the binding site sequences  
  ------- ------------------------------- ---------------- ----------- ----------------------------------------------- -----------------------------
  1            1201337436/rs45576939       g.10370(G\>A)    Intron 4                   **hnRNP.K1K2**                  
                                                                                         CCCCATCCCCA                            CCCCATCCCCA
                                                                                           GCCCAT                                 GCCCAT
                                                                                             \_                                   TCCCCA
  2           1201332603/rs483352834       g.15179 (C\>T)   Intron 10                     **SRP20**                    
                                                                                          AGCTTCAGC                                 \_
                                                                                         **ASF/SF2**                   
                                                                                    CTGAACTCACCCATAAAGACC               CTGAACTCACCCATAAAGACCACAAGT
                                                                                          **C35S**                     
                                                                                       GACCCAAGCTTCAG                            GACCACAA
                                                                                         **U2AF65**                    
                                                                                             \_                                    TTTC

Polymorphic SNPs {#s2e}
----------------

The chi-square and fisher exact probability test was done to test the significance of polymorphic SNPs that were observed in this study ([Table 5](#pone-0101451-t005){ref-type="table"}). We have compared the genotype and allele frequencies of these SNPs (NCBI database; [www.ncbi.nlm.nih.gov/projects/SNP/snp](http://www.ncbi.nlm.nih.gov/projects/SNP/snp)), with HapMap population\'s data, ([HER_ASIAN-PANEL; HER_HISP-PANEL; HER_CEPH-PANEL; HER_YORUB-PANE]{.ul}).

10.1371/journal.pone.0101451.t005

###### Chi-square and Fisher Exact Probability Test for SNP\'s found in this study.

![](pone.0101451.t005){#pone-0101451-t005-5}

  SNPs             Alleles        Controls (%)   DCM (%)   Odds Ratio   0.95 Confidence Intervals (Observed)   Chi-square   Fisher Exact Probability Test                   
  ----------- ------------------ -------------- --------- ------------ -------------------------------------- ------------ ------------------------------- ------- -------- -------
  5 bp pol     Deletion allele        56.5         69        1.679                      0.94                      2.99                  0.107               0.079   0.0534   0.107
               Insertion allele       43.5         31                                                                                                                       
  rs3729842      Major allele          95          90        0.474                     0.156                     1.411                  0.28                0.18     0.14    0.282
                 Minor allele          5           10                                                                                                                       
  rs3729843      Major allele          62          57        0.813                     0.462                     1.431                  0.57                0.471    0.28    0.565
                 Minor allele          38          43                                                                                                                       
  rs3729547      Major allele          80          81        1.066                     0.529                     2.146                    1                 0.862    0.5       1
                 Minor allele          20          19                                                                                                                       
  rs1104859      Major allele          71          78        1.448                     0.763                     2.748                  0.33                0.256    0.17    0.33
                 Minor allele          29          22                                                                                                                       
  rs2275863      Major allele          76          81        1.346                     0.683                     2.653                  0.49                0.389   0.246    0.491
                 Minor allele          24          19                                                                                                                       
  rs3729845      Major allele         100          98          \-                        \-                        \-                    \-                  \-     0.249    0.497
                 Minor allele          0            2                                                                                                                       

\*SNP- single nucleotide polymorphism, DCM- Dilated cardiomyopathy.

*a) SNP*-rs3729842: The homozygous mutant allele was exclusively observed in DCM and completely absent in the normal controls and HapMap populations (ASW, CHB, LWK, MKK) ([Fig. 1D](#pone-0101451-g001){ref-type="fig"} and, [Fig. 4A and 4B](#pone-0101451-g004){ref-type="fig"}). *b) SNP*-rs3729843: The allele frequencies of DCM have matched only with MXL, TSI, HapMap populations. The minor allele frequency was low in CEU population, while it was completely absent in two (LWK and YRI) HapMap populations ([Fig. 1G](#pone-0101451-g001){ref-type="fig"} and, [Fig. 4A and 4B](#pone-0101451-g004){ref-type="fig"}). *c) SNP*-rs3729845: About 4%of heterozygous genotype was observed in DCM, but it was completely absent in the controls, and two (CHB, JPT) of the HapMap populations ([Fig. 1E](#pone-0101451-g001){ref-type="fig"} and, [Fig. 4A and 4B](#pone-0101451-g004){ref-type="fig"}). *d) SNP*-rs3729547: The frequency of mutant homozygous allele was 7% in DCM as seen in Gujarati Indians GIH (Hap-map sample), but it was as low as 3% in controls ([Fig. 1J](#pone-0101451-g001){ref-type="fig"} and, [Fig. 4A and 4B](#pone-0101451-g004){ref-type="fig"}). *e) SNP*-rs1104859: The percentage of homozygous mutant allele was 13% in DCM, it was very low (6%) in controls. The frequency of the heterozygous genotype was found to be high in CHB, CHD, JPT, HapMap population\'s ([Fig. 1F](#pone-0101451-g001){ref-type="fig"} and, [Fig. 4 A and B](#pone-0101451-g004){ref-type="fig"}).

![A. The genotype frequencies of SNPs (rs3729842, ra3729843, rs3729845, rs3729547, rs1104859) in the present study were compared with HapMap samples (various populations).\
**B**. The Allele frequencies of SNPs (rs3729842, rs3729843, rs3729845, rs3729547, rs1104859) in the present study were compared with HapMap samples (various populations). HapMap samples (various populations)- ASW, African Ancestry in SW USA; CEU, CEPH Collection; CHB, Han Chinese in Beijing, China; CHD, Chinese in Metropolitan Denver, CO; GIH, Gujarati Indians in Houston, TX; JPT, Japanese in Tokyo, Japan; LWK, Luhya in Webuye, Kenya; MEX, Mexican Ancestry in LA,CA; MKK, Maasai in Kinyawa, Kenya; TSI, Toscani in Italia; YRI, Yoruba in Ibadan, Nigeria; CON-controls; HCM-hypertrophic cardiomyopathy; DCM-dilated cardiomyopathy.](pone.0101451.g004){#pone-0101451-g004}

Linkage disequilibrium {#s2f}
----------------------

Plotting of all the SNPs observed in the present study had revealed a strong linkage disequilibrium among three SNPs; rs3729547 (C/T), rs3729843 (G/A), rs3729842 (C/T), ([Fig. 1J, 1G](#pone-0101451-g001){ref-type="fig"} and, [1D](#pone-0101451-g001){ref-type="fig"} and [Table 1](#pone-0101451-t001){ref-type="table"}), respectively, which were about 2.0 kb apart, in both HCM [@pone.0101451-Reich1] and DCM ([Fig. 5](#pone-0101451-g005){ref-type="fig"}).

![Three SNPs, \[rs3729547 (C/T), rs3729843 (G/A), rs3729842 (C/T)\], (Table.1; [Fig.1D, 1G, 1J](#pone-0101451-g001){ref-type="fig"}) in TNNT2 gene observed in the present study, which were about 2.0 kb apart had shown high Linkage disequilibrium (LD).\
The bright red color indicates very strong LD (LOD = 2D′ = 1), white color no LD (LOD\<2D′\<1), and pink (LOD = 2D′\<1) and blue (LOD\<2D′ = 1) indicate intermediate LD (the standard color scheme is used to display LD). The values in the LD blocks show the r2 values in percentages or multiplied by 100.](pone.0101451.g005){#pone-0101451-g005}

A 5 bp INDEL (CTTCT) polymorphism {#s2g}
---------------------------------

A 5 bp (*CTTCT*) polymorphism ([Fig. 1M;a-c](#pone-0101451-g001){ref-type="fig"}) that results in skipping of exon 4 of *TNNT2* during splicing was not significant, when compared to normal controls, it was found to be almost equal in DCM however the deletion frequency was high in HCM [@pone.0101451-Rani2]. We have also further compared the 5 bp (CTTCT) polymorphic frequencies in 2092 randomly selected individuals belonging to 39 ethnic and endogamous populations from 19 states of India ([Table 6](#pone-0101451-t006){ref-type="table"}), with DCM and HCM [@pone.0101451-Rani2] ([Fig. 6 A and B](#pone-0101451-g006){ref-type="fig"}).

![A. The genotype frequency of 5(*cTnT*) gene of DCM, HCM and controls in the present study were compared with the randomly selected individuals from 19 states of India.\
**B**. The Allele frequency of 5 bp polymorphism observed in Troponin T (*cTnT*) gene of DCM, HCM and controls in the present study were compared with the randomly selected individuals from 19 states of India. Individuals from Rajasthan showed high frequency of Deletion allele, whereas the individuals of northeastern states and HER-YORUB-PANEL of Hap Map population showed high frequency of Insertion allele. AP, Andhra Pradesh; KA, Karnataka; TN, Tamil Nadu; MP, Madhya Pradesh; UP, Uttar Pradesh; MH, Maharashtra; GJ, Gujarat; RJ, Rajasthan; CG, Chhattisgarh; WB, West Bengal; HR, Haryana; NL, Nagaland; MZ, Mizoram; JH, Jharkhand; UK, Uttaranchal; JK, Jammu & Kashmir; OD, Orissa; AI, Andaman Islands; NI, Nicobar Islands; AS, Arunachal Pradesh; KE, Kerala; CN, normal controls; HC, Hypertrophic Cardiomyopathy; DC, Dilated Cardiomyopathy.](pone.0101451.g006){#pone-0101451-g006}

10.1371/journal.pone.0101451.t006

###### Details of 2092 random population samples from India used to study the 5 bp Deletion Polymorphism.

![](pone.0101451.t006){#pone-0101451-t006-6}

  S. No      States of India      Total Number (Each state)    Name of Tribes    No of Tribes   Genotype Frequency   Allele Frequency   Linguistic Family                                         
  ------- ---------------------- --------------------------- ------------------ -------------- -------------------- ------------------ ------------------- ------- ---- ------- -------- -------- ------------------
  1        Andhra Pradesh (AP)               246                   Mondi              44                20                45.45                16           36.36   8    18.18   59.085    40.9       Dravidian
                                                                Nai brahmins          46                23                  50                 16           34.78   7    15.21   59.78    40.21   
                                                                  Beastha             91                41                45.05                49           53.84   1    1.09    76.36    23.61   
                                                                  Yerkali             65                34                 52.3                29           44.61   2    3.07    48.65    29.22   
  2           Karnataka (KA)                 145                Gram vokkal           44                21                47.72                19           43.18   4    9.09    67.04    32.95       Dravidian
                                                                   Medar              50                27                  54                 10            20     13    26       47       53    
                                                                   Korova             31                14                45.16                12           38.7    5    16.12   61.28     38.7   
                                                                   Siddi              20                7                   35                  3            15     10    50      32.5     67.5   
  3          Tamil Nadu (TN)                 261                   Pillai            102                54                52.94                26           25.49   22   21.35   51.96    47.82       Dravidian
                                                                  Paravar             40                22                  55                  9           22.5    9    22.5      50       50    
                                                                 Arunthathi           83                54                65.06                29           34.93   0      0     67.46    32.53   
                                                                   Irula              36                16                  45                  4           10.81   16   43.24   33.78    66.75   
  4        Madhya Pradesh (MP)               249                   Saxena             86                39                45.34                35           40.69   12   13.95   63.36    36.62     Indo-European
                                                                   Bharia             42                20                47.61                12           28.57   10   23.8    52.37    47.605  
                                                                    Bhil              40                20                  50                 14            35     6     15       60       40    
                                                                 Chaurasia            81                35                 43.2                38           46.91   8    9.87    68.51    31.47   
  5         Uttar Pradesh (UP)               44                    Agaria             44                24                54.54                14           31.81   6    13.63   59.08     40.9     Indo-European
  6          Maharashtra (MH)                227                Mahadeo Koli          82                37                45.12                32           39.02   13   15.85   61.58    38.41     Indo-European
                                                               Maratha desai          62                38                 61.2                16           25.8    8    12.9     56.4     43.5   
                                                                   Warli              83                43                 51.8                31           37.34   9    10.84   63.24    36.74   
  7            Gujarat (GJ)                  231                   Gamit              88                37                42.04                43           48.86   8    9.09    69.88    30.11    Proto-Australoid
                                                                   Siddi              63                34                53.96                 8           12.69   21   33.33   39.67    60.31     Indo-European
                                                                   Patel              80                33                41.25                32            40     15   18.75   60.625   39.375  
  8           Rajasthan (RJ)                 153                    Jain              86                36                41.86                43            50     7    8.13    70.93    29.07     Indo-European
                                                                   Meena              67                29                 38.8                32           47.76   6    8.95     70.1     29.9   
  9         Chhattisgarh (CG)                52                    Sindhi             52                25                48.07                20           38.46   7    13.46   62.49    37.49     Indo-European
  10         West Bengal (WB)                60                    Subba              14                6                 42.85                 8           57.14   0      0     78.565   21.425    Tibeto-Burman
                                                                   Mixed              46                11                  44                  6            24     8     32       46       54      Indo-European
  11           Haryana (HR)                   9                      Ho               9                 4                 44.44                 4           44.44   1    11.1    66.66    33.32     Austro-Asiatic
  12          Nagaland (NL)                  71                   Ao Naga             34                13                38.23                 7           20.58   14   41.17   39.695   60.285    Tibeto-Burman
                                                               Chakesang Naga         37                17                45.94                 4           10.81   16   43.24   33.78    66.75     Tibeto-Burman
  13           Mizoram (MZ)                  26                     Mizo              26                9                 34.61                 8           30.76   9    34.61   48.065   51.91     Tibeto-Burman
  14          Jharkhand (JH)                 63                    Gorait             63                31                 49.2                27           42.85   5    7.93    67.45    32.53     Austro-Asiatic
  15         Uttaranchal (UK)                 5                     Sah               5                 2                   40                  1            20     2     40       40       60        Dravidian
  16       Jammu & Kashmir (JK)              15               Kashmiri Pandits        15                7                 46.66                 5           33.33   3     20     56.66    43.33     Indo-European
  17           Orissa (OD)                   85                    Kandha             85                41                48.23                20           23.52   24   28.23   47.635   52.345    Indo-European
  18       Andaman islands (AI)              39                  Andamanese           16                5                 31.25                10           62.5    1    6.25    78.125   21.875      Andamanese
                                                                    Onge              23                12                52.17                 3           13.04   8    34.78   39.125   60.865         Onge
  19       Nicobar islands (NI)              23                  Nicobarese           23                15                65.21                 5           21.73   3    13.04   54.335   45.645      Nicobarese
  20            Assam (AS)                   27                    Nyshi              27                11                40.74                 7           25.92   9    33.33   46.29     53.7     Tibeto-Burman
  21           Kerala (KE)                   61                   Kurumban            61                23                 37.7                29           47.54   9    14.05   66.39     33.6       Dravidian

I/D Insertion/Deletion, D/D Deletion/Deletion, I/I Insertion/Insertion.

Discussion {#s3}
==========

It has been shown initially that the mutations in the *cTnT* gene are responsible for approximately 15% cases of familial hypertrophic cardiomyopathy (FHCM) [@pone.0101451-Watkins1]. However, subsequent studies have identified *cTnT* gene mutations in familial dilated (FDCM) [@pone.0101451-Hershberger5], restrictive (RCM) [@pone.0101451-Pinto1], and left ventricular noncompaction [@pone.0101451-Luedde1], cardiomyopathies. Interestingly, our study of *cTnT* gene in 147 dilated cardiomyopathy (DCM) patients against 207 ethnically matched healthy controls had revealed a total of 15 SNPs and a 5 bp INDEL, including a novel heterozygous C→T at nucleotide g.14351 in exon 10 of *cTnT* gene in a DCM patient. The mutation had substituted polar-neutral amino acid tryptophan for a highly conserved wild type basic amino acid arginine within the amino terminal tail at residue 144 (R144W) of *cTnT*.

The R144W mutation was found to be within the tropomyosin-binding domain of *cTnT* and alters the charge of the residue, so it is expected to have a significant impact on the structure and function of the protein. Later, screening of this mutation in all the available members of a large four generations family had revealed the presence of this heterozygous R144W mutation in three affected individuals of the family ([Fig. 2](#pone-0101451-g002){ref-type="fig"}), suggesting that it is an autosomal dominant trait. However, evaluation of 207 unrelated healthy control individuals and 162 HCM patients [@pone.0101451-Rani2] did not show this (R144W) mutation.

The proband and 3 individuals positive for R144W mutation had showed clinical features, that are typical for DCM, specifically, left ventricular dilatation and depressed contractile function ([Table 2](#pone-0101451-t002){ref-type="table"}). The sudden cardiac death (SCD) was also been reported in the family, two individuals, who were diagnosed with dilated cardiomyopathy (DCM), had died due to severe congestive heart failure at the age of 45 and 25 years, these deceased individuals were developed their cardiac condition in the second and third decades of their life, respectively. However, a 66-year-old individual in the same family has started having mild symptoms only at his sixties ([Fig. 2](#pone-0101451-g002){ref-type="fig"}). Thus, the age of onset and the severity of the disease are highly variable within the family, suggesting that, in many cases, the scenario is more complex, if the secondary etiological factors, such as lifestyle and environment are involved ([Fig. 2](#pone-0101451-g002){ref-type="fig"}).

In addition, this amino acid tail residue arginine at 144 in human *cTnT* is evolutionarily conserved across species, including mouse, rat, chicken, quail, and nematode etc. ([Fig. 3](#pone-0101451-g003){ref-type="fig"}). It appears that the amino-terminal tail of *cTnT* is essential for assembly and anchoring of the troponin-tropomyosin complex onto the thin filament [@pone.0101451-Hinkle1]--[@pone.0101451-Sehnert1]. The troponin-tropomyosin complex is a Ca^2+^ sensitive switch that regulates actin-myosin interaction. The troponin complex (Troponins T, I, and C) is anchored to tropomyosin predominantly by troponin T and to a lesser extent by troponin I, and Troponin C interacts with these two troponins T and I \[33\]. During systole, Ca^2+^ binds to *cTnC* and initiates conformational changes of the troponin complex that attenuate the inhibitory effect of *cTnI*. Results in the release of active sites of the actin gene and this enables the myosin head of the thick filament to interact with it and generate force. The Ca^2+^ concentration controls *cTnC-cTnT* interaction, which is important for regulating sliding velocity between thick and thin filaments. Interestingly, recent studies have proposed that *cTnT* is critical, not only for the structural integrity of the troponin complex, but also for sarcomere assembly and cardiac contractility [@pone.0101451-Hinkle1]--[@pone.0101451-Sehnert1].

In general, most of the reported mutations that were responsible for the disease phenotype of dilated (DCM) were in the amino-terminal tail of *cTnT* (exons 10 and 13) [@pone.0101451-Kamisago1]--[@pone.0101451-Li2]. Moreover, no mutations responsible for familial hypertrophic cardiomyopathies have ever been identified in either of these exons, 10 and 13 [@pone.0101451-Li2]. Study of [@pone.0101451-Mirza1] some of the published mutations \[(R131W [@pone.0101451-Mogensen1] and R141W [@pone.0101451-Li2] in exon 10), and (Lys 210 del \[34,35\], R205L \[35\] in exon 13)\], in the amino-terminal tail of *TNNT2* gene reported to be responsible for dilated cardiomyopathy (DCM); along with other 4 thin filaments mutations, reconstituted with a 1∶1 ratio of mutant∶wild type proteins, all showed reduced Ca^2+^ sensitivity of activation in ATPase and motility assays, and all showed lower maximum Ca^2+^ activation.

Integration of the cTnT mutations (R141W [@pone.0101451-Li2] and R205L [@pone.0101451-Mogensen1], into skinned guinea pig cardiac trabeculae also reduced Ca^2+^ sensitivity of force generation [@pone.0101451-Mirza1]. Therefore, diverse thin filament DCM mutations appeared to affect different aspects of regulatory function, nevertheless changing contractility in a consistent manner. Further [@pone.0101451-Mirza1]stated that the DCM mutations depressed myofibrillar function, an effect opposite to that of HCM-causing thin filament mutations, and suggested that decreased contractility might trigger pathways that ultimately lead to the clinical phenotype. Generated knock-in mice [@pone.0101451-Du1] with a reported mutation, K210-del [@pone.0101451-Kamisago1], [@pone.0101451-Mogensen1] in exon 13 of *cTnT* gene, and found that cardiac muscle fibers from mutant mice showed significantly lower Ca^2+^ sensitivity in force generation than those from wild type mice [@pone.0101451-Du1].

Compound heterozygosity (double and triple mutations) had been reported to cause HCM phenotype [@pone.0101451-Ingles1], [@pone.0101451-Girolami1]. Therefore, we have further analyzed the patient and three of his family members carrying R144W mutation having DCM phenotype with eight other genes (*β-MYH7, MYBPC3, TPM1, TNNI3, TTN, ACTC, MYL2* and *MYL3*), to rule out compound heterozygosity. Our analysis revealed that none of these 4 individuals showed any disease causing mutations in eight of the above-mentioned genes, except with few polymorphic variants. This had further confirmed that the missense mutation R144W in *cTnT* gene is essentially responsible for FDCM phenotype in our study family.

Of 15 SNPs, we have identified a novel splice acceptor site mutation (G→A) at g.16283 in intron 12 (rs) of *cTnT* gene in a 63-year-old male DCM patient ([Table 1](#pone-0101451-t001){ref-type="table"}; [Fig. 1B](#pone-0101451-g001){ref-type="fig"}). Unfortunately, we were unable to get the family samples for further analysis. The splice acceptor site variant might create an alternative acceptor site for splicing, which may results in the inclusion or exclusion of amino acid (glutamine) or the complete skipping of the exon (9 nucleotides). As a result, this alternately spliced transcript might form isoforms, which may be expressed in the human heart are expected to be responsible for the disease phenotype; however, this need to be studied further.

Interestingly, we also found a variant C→T at g.15179 in intron11 of *cTnT* gene exclusively in a DCM, was predicted to affect splicing. But we have unable to collect the family samples. We have compared the genotype and allele frequencies of polymorphic SNPs observed in this study with HapMap (NCBI database; [www.ncbi.nlm.nih.gov/projects/SNP/snp](http://www.ncbi.nlm.nih.gov/projects/SNP/snp)) populations (HER_ASIAN-PANEL; HER_HISP-PANEL;HER_CEPH-PANEL; HER_YORUB-PANE) (Fig.).

We have compared the 5 bp INDEL frequencies in 147 DCM against 207 healthy controls along with 2092 randomly selected individuals belonging to 39 ethnic and endogamous populations inhabited in 19 states of India ([Table 6](#pone-0101451-t006){ref-type="table"}). Our study revealed that the 5 bp INDEL frequencies were found to be almost same in DCM and the controls; nevertheless this 5 bp INDEL frequency was high in South and the Northwest regions of Indian populations, and HCM [@pone.0101451-Rani2] ([Fig. 6B](#pone-0101451-g006){ref-type="fig"}).

In conclusion, we strongly suggest that the novel unique/private R144W mutation identified in our present study is associated with FDCM. The high level of endogamy in Indian populations along with the influence of evolutionary forces such as genetic drift, fragmentation and long-term isolation, has kept the Indian populations diverse and distant [@pone.0101451-Chaubey1]. Hence, the unique mutation observed in this study is not surprising. Our study further suggests that it is important to understand the fundamental genetics (mutation) cause and its impact on disease phenotype, this will certainly lead to adopt novel approaches for the diagnosis and treatment of disease.

Materials and Methods {#s4}
=====================

Ethical statement {#s4a}
-----------------

All of the DNA samples analyzed in the present study were derived from blood samples that were collected with the informed written consent of the donors. The Institutional Ethics Committee of Care Hospitals, Hyderabad, India; and the CSIR-Centre for Cellular and Molecular Biology, Hyderabad, India, have approved the study. This study conforms to the principles outlined in the Declaration of Helsinki (WMA World Medical Association Declaration of Helsinki). The study subjects were all South Indian patients with dilated cardiomyopathy (DCM), diagnosed based on the NYHA (New York Heart Association, 1994), and WHO ([www.who.int/cardiovascular_diseases](http://www.who.int/cardiovascular_diseases)) guidelines.

Inclusion criteria {#s4b}
------------------

Dilated cardiomyopathy (DCM) is characterized by left ventricular enlargement (LVE), and when echocardiography demonstrated a depressed systolic dysfunction with an ejection fraction (LVEF) \<45--50% and/or fractional shortening \<25%.

Exclusion criteria {#s4c}
------------------

Patients with concomitant disease like; autoimmune disease, cancer, as well as patients with coronary artery disease (CAD), ventricular outflow tract obstructions and with advanced chronic renal failure (CRF), were excluded.

Genetic analysis {#s4d}
----------------

We have sequenced all the exons, including the exon-intron boundaries (5373 bp length) of Troponin T2 (*cTnT*) gene ([Table S1](#pone.0101451.s002){ref-type="supplementary-material"}), of clinically well-characterized 147 DCM against ethnically matched 207 healthy controls. ([Text S1](#pone.0101451.s001){ref-type="supplementary-material"})

In silico analysis {#s4e}
------------------

To evaluate whether the SNPs observed exclusively in DCM have any potential cause for the defect in splicing, we have analyzed these sites with ASD Workbench wrapper (<http://www.ebi.ac.uk/asd-srv/wb.cgi>) tools, such as poly-pyrimidine tract (PPT), and branch-points (BP). The novel SNPs observed in this study were subjected to identify the presence of PPT and BP binding sites for splicing factors, and exonic splicing enhancers/silencers (ESE/ESS) or intronic splicing enhancers/silencers (ISE/ISS), respectively. Splicing Rainbow tool searches for the SR proteins (serine/arginine-rich) as well as hnRNP motifs.
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